Bioequivalent Liquid Blood Treatment Bioreactor
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for treating blood composition and function disorders are limited in their ability to comprehensively and complexly modify blood composition, often resulting in adverse effects and insufficient clinical outcomes due to lack of selectivity and systemic impact.
Innovation Solution
A method involving extracorporeal contact of patient blood or plasma with a bioequivalent liquid containing granulocytes, thrombocytes, and erythrocytes at specific concentrations, which mimics the functionality of whole blood to restore organ functions and treat disorders by biospecific adsorption and neutralization.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Manufacturing precision
If conventional extracorporeal blood treatment methods are used to remove harmful substances, then selective removal of individual harmful substances is achieved, but only a selective effect is obtained with limited comprehensive modification capability
Solution Approach 1:
The patent employs a bioreactor system containing multiple functional cell types (granulocytes, macrophages, lymphocytes, and hepatocytes) that collectively provide diverse therapeutic functions including toxin removal, immunomodulation, and tissue regeneration, enabling comprehensive blood composition modification rather than single-target treatment
2Manufacturing precision
If medicamentous therapies are used to treat blood disorders, then selective effects are achieved through systemic agents, but adverse drug reactions occur and comprehensive normalization is insufficient
Solution Approach 1:
The bioreactor system utilizes patient's own blood components (granulocytes, macrophages, lymphocytes) that are stimulated and activated in vitro to provide self-regulating therapeutic effects, eliminating the need for external pharmacological agents and their associated adverse reactions while maintaining selective therapeutic action
Solution Approach 2:
The patent modifies physiological parameters of blood components through controlled in vitro activation and differentiation processes, changing the functional state of cells to achieve therapeutic effects without introducing exogenous substances that could cause adverse reactions
3Quantity of substance
If blood transfusion is used to replace deficient blood components, then deficiency is corrected, but complex changes in blood composition cannot be achieved
Solution Approach 1:
The bioreactor system dynamically adjusts the composition and function of blood components through real-time cellular activation, differentiation, and interaction processes, enabling comprehensive and adaptive modification of blood composition rather than static replacement
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This approach enables comprehensive and complex modification of blood composition, enhancing clinical outcomes by diluting toxins, biospecifically adsorbing harmful substances, and promoting organ-regenerative processes, while minimizing adverse effects.
Implementation Method 1
This approach enables comprehensive and complex modification of blood composition, enhancing clinical outcomes by diluting toxins
Implementation Method 2
biospecifically adsorbing harmful substances
Data Source
AI summary
The present invention relates to a method for treating blood composition disorders and blood function disorders. Said method comprises steps, in which blood or blood plasma of a patient is brought into extracorporeal contact with a second fluid (bioequivalent), wherein said second fluid is blood or modified blood, which comprises at least granulocytes, thrombocytes, and erythrocytes. Furthermore, the invention relates to devices for performing said method and to the use of such a device or blood or modified blood, which comprises granulocytes, thrombocytes, and erythrocytes, for treating blood composition disorders and blood function disorders.